Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arcturus Therapeutics Holdings Inc shares valued at $249,121 were sold by Chivukula Pad on Oct 15 ’24. At $20.76 per share, Chivukula Pad sold 12,000 shares. The insider’s holdings dropped to 435,334 shares worth approximately $7.33 million following the completion of this transaction.
Also, Chivukula Pad purchased 12,000 shares, netting a total of over 249,121 in proceeds.
Before that, SASSINE ANDY had sold 50,000 shares from its account. In a trade valued at $1,601,500, the Chief Financial Officer traded Arcturus Therapeutics Holdings Inc shares for $32.03 each. Upon closing the transaction, the insider’s holdings decreased to 50,000 shares, worth approximately $3.71 million.
As published in their initiating research note from BTIG Research on January 28, 2025, Arcturus Therapeutics Holdings Inc [ARCT] has been a Buy and the price target has been revised to $41. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid August. As of December 13, 2023, Canaccord Genuity has initiated its “Buy” rating for ARCT. Earlier on July 24, 2023, William Blair initiated its rating. Their recommendation was “an Outperform” for ARCT stock.
Analyzing ARCT Stock Performance
During the last five days, there has been a surge of approximately 0.60%. Over the course of the year, Arcturus Therapeutics Holdings Inc shares have dropped approximately -0.77%. Shares of the company reached a 52-week high of $21.26 on 01/07/25 and a 52-week low of $15.82 on 01/23/25. A 50-day SMA is recorded $17.22, while a 200-day SMA reached $22.55. Nevertheless, trading volume fell to 0.51 million shares from 0.34 million shares the previous day.
Support And Resistance Levels for Arcturus Therapeutics Holdings Inc (ARCT)
According to the 24-hour chart, there is a support level at 16.22, which, if violated, would cause prices to drop to 15.59. In the upper region, resistance lies at 17.28. The next price resistance is at 17.71. RSI (Relative Strength Index) is 47.74 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.49, which suggests the price will decrease in the coming days. Percent R is at 80.08%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Which companies own the most shares of Arcturus Therapeutics Holdings Inc (ARCT)?
On May 11, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and upgraded coverage with a $51.
